Roche seeking earlier use for Lunsumio in FL on Phase III data

Phase 3LunsumioPositive

AI Analysis

Summary

Roche is leveraging Phase III data for Lunsumio to seek approval for second-line use in follicular lymphoma, building on its existing accelerated approval for third-line indication.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Phase III data expected to support earlier (second-line) use; currently has accelerated approval for third-line use

Importance:6/10

Sentiment:

0.50

follicular lymphomaaccelerated approvallabel expansionsecond-line treatment

Related Companies

$RHHBY

Read the original article

Published by Clinical Trials Arena on September 18, 2026 10:12 AM

Read Original